4,478 Shares in Boston Scientific Corporation (NYSE:BSX) Bought by MQS Management LLC

MQS Management LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,478 shares of the medical equipment provider's stock, valued at approximately $452,000.

Other hedge funds also recently bought and sold shares of the company. Colonial Trust Co SC increased its holdings in Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after buying an additional 260 shares during the last quarter. Investment Management Corp VA ADV bought a new stake in Boston Scientific in the fourth quarter worth approximately $25,000. Sunbeam Capital Management LLC bought a new stake in Boston Scientific in the fourth quarter worth approximately $26,000. Ameriflex Group Inc. acquired a new position in shares of Boston Scientific during the 4th quarter worth $31,000. Finally, Fourth Dimension Wealth LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at $36,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.7%

Shares of BSX opened at $103.16 on Monday. The stock's 50-day moving average price is $103.42 and its 200 day moving average price is $100.66. The company has a quick ratio of 0.88, a current ratio of 1.45 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $152.62 billion, a price-to-earnings ratio of 75.30, a P/E/G ratio of 2.68 and a beta of 0.68. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $107.53.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 earnings per share. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on BSX. Royal Bank Of Canada increased their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Barclays increased their price objective on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Truist Financial boosted their target price on Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. BTIG Research reaffirmed a "buy" rating and set a $124.00 target price on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Robert W. Baird lifted their price target on shares of Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Twenty-two equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and an average price target of $116.09.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the sale, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. The trade was a 10.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the sale, the executive vice president directly owned 22,235 shares in the company, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 461,970 shares of company stock worth $47,755,193. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.